Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Posts Nearly 30 Percent Revenue Jump in Q1

NEW YORK (GenomeWeb News) - Luminex last week said first-quarter revenue increased 28 percent as R&D spending rose 23 percent and profit shrank by 75 percent.
 
Total receipts for the three months ended March 31, 2007, increased to $16.6 million from $13 million year over year. Results included one month of revenues from Tm Bioscience, which Luminex acquired on March 1 and has renamed Luminex Molecular Diagnostics.

 

Luminex said it is now reporting results for two business segments: the Technology Group, which includes system sales to partners, raw bead sales, royalties, and service and support of the core technology; and the Assay Group, which includes the Luminex Bioscience Group and Luminex Molecular Diagnostics.
 
First-quarter revenues for the Technology Group rose to $15.7 million from $13 million in the first quarter of 2006. The Assay Group posted revenues of $1.2 million in the current quarter, compared to zero revenues in the prior-year period.
 
Luminex CEO Patrick Balthrop said in a statement that the quarter was a “strong start” for the year, with record revenues and profit coming from the company's life sciences segment.
 
System revenue rose 43 percent to $5.7 million; consumables fell 13 percent to $4.8 million; royalties rose 41 percent to $2.5 million; reagent revenue was $1.1 million compared with no revenue in the previous year's first quarter; service revenue increased 24 percent to $1 million; and other revenue increased 53 percent to $1.4 million.
 
R&D spending increased to $2.7 million from $2.2 million year over year.
 
The company said its net income fell to $136,000 from $526,000 in the year-ago period.
 
Luminex said it had around $16.2 million in cash and equivalents and $3.5 million in short-term investments as of March 31.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.